Alimera Sciences organizacji Cena/wartość księgowa
Jaka jest wartość Cena/wartość księgowa organizacji Alimera Sciences?
Wartość Cena/wartość księgowa organizacji Alimera Sciences Inc. to 0.36
Jaka jest definicja Cena/wartość księgowa?
Wskaźnik ceny do sprzedaży(Price to book ratio) reprezentuje stosunek wartości akcji spółki do wartości księgowej na akcję.
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
Cena/wartość księgowa firm w Health Care sektor na NASDAQ w porównaniu do Alimera Sciences
Czym się zajmuję organizacja Alimera Sciences?
alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.
Firmy z cena/wartość księgowa podobne do Alimera Sciences
- Wartość Cena/wartość księgowa organizacji NWS to 0.36
- Wartość Cena/wartość księgowa organizacji Koenig & Bauer AG to 0.36
- Wartość Cena/wartość księgowa organizacji Best Pacific International to 0.36
- Wartość Cena/wartość księgowa organizacji Bambuser AB (publ) to 0.36
- Wartość Cena/wartość księgowa organizacji Gravity (India) to 0.36
- Wartość Cena/wartość księgowa organizacji Gemdale Properties and Investment to 0.36
- Wartość Cena/wartość księgowa organizacji Alimera Sciences to 0.36
- Wartość Cena/wartość księgowa organizacji Tritax EuroBox plc to 0.36
- Wartość Cena/wartość księgowa organizacji Vasta Platform to 0.36
- Wartość Cena/wartość księgowa organizacji EyePoint Pharmaceuticals Inc to 0.36
- Wartość Cena/wartość księgowa organizacji Valeura to 0.36
- Wartość Cena/wartość księgowa organizacji Devernois S.A to 0.36
- Wartość Cena/wartość księgowa organizacji Inozyme Pharma to 0.37